Healthcare professionals are required to complete training before prescribing Tolvaptan. Please follow the link to access the Tolvaptan Teva Training For Healthcare Professionals and to register your completion of this training. These materials provide important safety information on the risks of Tolvaptan Teva treatment, including liver toxicity, pregnancy prevention, monitoring requirements, dose and method of administration information, as well as the process for reporting adverse events. This training does not replace the Summary of Product Characteristics (SmPC), which should be read thoroughly before prescribing or dispensing Tolvaptan Teva. Patients should also be advised to read the Patient Information Leaflet (PIL).

Tolvaptan Teva is a specialist product for which additional training is available prior to prescribing. If you wish to undertake this training, please visit https://www.tevauk.com/hcp/tolvaptan-hcp/ to register and complete the training. This guide has been developed for prescribers and healthcare professionals (HCPs) involved in the treatment of patients using Tolvaptan Teva. This document summarises important information on the potential risk of hepatic toxicity and provides guidance on how to manage this risk. In addition, it provides important information about pregnancy prevention before and during the treatment with Tolvaptan Teva.

Tolvaptan Teva is a specialist product for which additional training is available prior to prescribing. If you wish to undertake this training, please visit https://www.tevauk.com/hcp/tolvaptan-hcp/ to register and complete the training. This patient alert card should be used by patients who have been prescribed medicines containing tolvaptan and should carry with them at all times when taking this medicine. This card contains important safety information that patient needs to be aware of before, during, and after treatment with Tolvaptan Teva.

Tolvaptan Teva is a specialist product for which additional training is available prior to prescribing. If you wish to undertake this training, please visit https://www.tevauk.com/hcp/tolvaptan-hcp/ to register and complete the training. The guide should be provided to patients by the prescribing physician and includes a description of the risks of treatment, guidance on what to do in the event of risks occurring and an overview of treatment monitoring.

Tolvaptan Teva is a specialist product for which additional training is available prior to prescribing. If you wish to undertake this training, please visit https://www.tevauk.com/hcp/tolvaptan-hcp/ to register and complete the training. This material is provided by Teva UK Limited as a licence requirement for this medicine and forms part of the Risk Management Plan.